HRP20120046T1 - Nerameksan za uporabu kod liječenja subakutnog tinitusa - Google Patents

Nerameksan za uporabu kod liječenja subakutnog tinitusa Download PDF

Info

Publication number
HRP20120046T1
HRP20120046T1 HR20120046T HRP20120046T HRP20120046T1 HR P20120046 T1 HRP20120046 T1 HR P20120046T1 HR 20120046 T HR20120046 T HR 20120046T HR P20120046 T HRP20120046 T HR P20120046T HR P20120046 T1 HRP20120046 T1 HR P20120046T1
Authority
HR
Croatia
Prior art keywords
neramexane
pharmaceutically acceptable
acceptable salt
use according
tinnitus
Prior art date
Application number
HR20120046T
Other languages
English (en)
Croatian (hr)
Inventor
Ellers-Lenz Barbara
Rosenberg Tanja
Krueger Hagen
Althaus Michael
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of HRP20120046T1 publication Critical patent/HRP20120046T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Percussion Or Vibration Massage (AREA)
HR20120046T 2007-09-12 2012-01-16 Nerameksan za uporabu kod liječenja subakutnog tinitusa HRP20120046T1 (hr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US99339607P 2007-09-12 2007-09-12
EP07253630 2007-09-12
US6708308P 2008-02-25 2008-02-25
US6693108P 2008-02-25 2008-02-25
US6702608P 2008-02-25 2008-02-25
EP08004776 2008-03-14
EP08004778 2008-03-14
EP08004777 2008-03-14
PCT/EP2008/007421 WO2009033652A1 (en) 2007-09-12 2008-09-10 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus

Publications (1)

Publication Number Publication Date
HRP20120046T1 true HRP20120046T1 (hr) 2012-02-29

Family

ID=40451596

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120046T HRP20120046T1 (hr) 2007-09-12 2012-01-16 Nerameksan za uporabu kod liječenja subakutnog tinitusa

Country Status (21)

Country Link
US (6) US20110086916A1 (ko)
EP (6) EP2200598A1 (ko)
JP (6) JP5613053B2 (ko)
KR (4) KR20100052556A (ko)
CN (4) CN101801366A (ko)
AR (3) AR071728A1 (ko)
AT (1) ATE532507T1 (ko)
AU (4) AU2008298017B2 (ko)
BR (2) BRPI0816690A2 (ko)
CA (4) CA2699209A1 (ko)
DK (1) DK2200600T3 (ko)
ES (5) ES2510565T3 (ko)
HR (1) HRP20120046T1 (ko)
MX (4) MX2010002733A (ko)
PL (1) PL2200600T3 (ko)
PT (1) PT2200600E (ko)
RU (1) RU2011137131A (ko)
SI (1) SI2200600T1 (ko)
TW (3) TW200918042A (ko)
WO (4) WO2009033650A1 (ko)
ZA (4) ZA201001262B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
WO2011160839A1 (en) 2010-06-24 2011-12-29 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN106535883A (zh) * 2014-04-28 2017-03-22 杏林制药株式会社 耳鸣患者的治疗用药剂
EP3138559A4 (en) * 2014-04-28 2017-10-25 Kyorin Pharmaceutical Co., Ltd. Drug for treatment of tinnitus patients
CA2999467C (en) 2014-10-23 2023-10-10 Arena Pharmaceuticals, Inc. Method of treating conditions related to the pgi2 receptor
PL3297628T3 (pl) * 2015-05-18 2021-12-06 Sensorion Azasetron do stosowania w leczeniu niedosłuchu
KR101893604B1 (ko) 2015-08-27 2018-08-30 경희대학교 산학협력단 칸디다 유틸리스 추출물을 포함하는 난청의 예방 또는 치료용 조성물
CN105924362B (zh) * 2016-02-05 2018-08-17 上海龙翔生物医药开发有限公司 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
KR102268893B1 (ko) 2020-01-16 2021-06-24 경북대학교 산학협력단 림노트릭스 속 knua002 균주를 포함하는 난청의 예방 또는 치료용 조성물
CN111477199B (zh) * 2020-04-02 2021-11-30 北京瑞迪欧文化传播有限责任公司 一种嵌入式音乐控制系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
CA2172509C (en) 1993-10-22 2010-08-24 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
DE19528388A1 (de) * 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AU4424697A (en) * 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
EP1009732B1 (en) * 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
JP2003531187A (ja) * 2000-04-26 2003-10-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的nmda受容体アンタゴニストとしてのシクロヘキシルアミン誘導体
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
JP2004021734A (ja) 2002-06-18 2004-01-22 Nokia Corp キーパッドおよびキーパッドシステム
US7086532B2 (en) * 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
EA010430B1 (ru) * 2003-05-27 2008-08-29 Форест Лэборэтериз, Инк. Сочетание антагониста nmda-рецептора и селективного ингибитора обратного захвата серотонина для лечения депрессии и других психических расстройств
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR20090033410A (ko) 2004-06-17 2009-04-02 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US20060264897A1 (en) * 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006096518A2 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Improved gacyclidine formulations
TWI265036B (en) * 2005-04-29 2006-11-01 Guo-Ming Huang Safety injector and method of operating the same
US8062205B2 (en) * 2005-05-18 2011-11-22 Gt Urological, Llc Drug elution for implantable incontinence devices
CN1896729A (zh) 2005-07-15 2007-01-17 复旦大学附属中山医院 纳米药物自组装双稳态量子线阵列及其制备方法
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
TW200819458A (en) * 2006-06-23 2008-05-01 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
PL2200600T3 (pl) * 2007-09-12 2012-04-30 Merz Pharma Gmbh & Co Kgaa Nerameksan do zastosowania w leczeniu podostrego szumu usznego
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives
AU2009291244A1 (en) * 2008-09-10 2010-03-18 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of cognitive impairment in tinnitus
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US20130296427A1 (en) * 2011-01-20 2013-11-07 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss

Also Published As

Publication number Publication date
CN101835469A (zh) 2010-09-15
CN101801366A (zh) 2010-08-11
JP5563461B2 (ja) 2014-07-30
US20110077304A1 (en) 2011-03-31
BRPI0816690A2 (pt) 2016-11-01
KR20100052559A (ko) 2010-05-19
CA2699209A1 (en) 2009-03-19
KR20100052557A (ko) 2010-05-19
CA2699207A1 (en) 2009-03-19
AU2008298017B2 (en) 2012-03-01
JP5784189B2 (ja) 2015-09-24
TW200922544A (en) 2009-06-01
CN101801365A (zh) 2010-08-11
TW200927087A (en) 2009-07-01
AU2008298017A1 (en) 2009-03-19
US20100298441A1 (en) 2010-11-25
US20170027885A1 (en) 2017-02-02
ES2596262T3 (es) 2017-01-05
US20110086916A1 (en) 2011-04-14
EP2200599A1 (en) 2010-06-30
AR071728A1 (es) 2010-07-14
AU2008298016B2 (en) 2012-02-02
CN101795679A (zh) 2010-08-04
WO2009033650A1 (en) 2009-03-19
ZA201001262B (en) 2011-07-27
MX2010002735A (es) 2010-04-01
AU2008298016A1 (en) 2009-03-19
EP2200599B1 (en) 2016-08-31
AR070025A1 (es) 2010-03-10
EP2386299A2 (en) 2011-11-16
ES2377253T3 (es) 2012-03-23
BRPI0816712A2 (pt) 2016-11-08
EP2386299A3 (en) 2012-05-02
JP5613053B2 (ja) 2014-10-22
EP2203163A1 (en) 2010-07-07
AU2008298018A1 (en) 2009-03-19
KR20100052556A (ko) 2010-05-19
MX2010002736A (es) 2010-04-01
DK2200600T3 (da) 2012-01-23
JP2010539116A (ja) 2010-12-16
CA2699210A1 (en) 2009-03-19
AU2008298015B2 (en) 2012-03-22
EP2203163B1 (en) 2014-08-27
JP5563460B2 (ja) 2014-07-30
US20150018425A1 (en) 2015-01-15
ES2510565T3 (es) 2014-10-21
US20100298440A1 (en) 2010-11-25
MX2010002733A (es) 2010-04-09
MX2010002734A (es) 2010-04-01
EP2386299B1 (en) 2016-07-13
JP2010539115A (ja) 2010-12-16
PL2200600T3 (pl) 2012-04-30
AU2008298018B2 (en) 2012-01-19
EP2548552A3 (en) 2013-10-16
SI2200600T1 (sl) 2012-03-30
EP2200598A1 (en) 2010-06-30
JP5784188B2 (ja) 2015-09-24
WO2009033651A1 (en) 2009-03-19
EP2200600A1 (en) 2010-06-30
EP2200600B1 (en) 2011-11-09
KR20100052558A (ko) 2010-05-19
ZA201001263B (en) 2011-07-27
AR070026A1 (es) 2010-03-10
US8877814B2 (en) 2014-11-04
AU2008298015A1 (en) 2009-03-19
JP2014221767A (ja) 2014-11-27
TW200918042A (en) 2009-05-01
EP2548552B1 (en) 2015-11-18
ATE532507T1 (de) 2011-11-15
RU2011137131A (ru) 2013-03-20
JP5612473B2 (ja) 2014-10-22
AU2008298018C1 (en) 2012-08-16
ES2604945T3 (es) 2017-03-10
EP2548552A2 (en) 2013-01-23
PT2200600E (pt) 2012-02-17
JP2010539118A (ja) 2010-12-16
JP2014221766A (ja) 2014-11-27
ES2562709T3 (es) 2016-03-07
ZA201001261B (en) 2011-08-31
WO2009033649A1 (en) 2009-03-19
CA2699213A1 (en) 2009-03-19
US9468610B2 (en) 2016-10-18
JP2010539117A (ja) 2010-12-16
ZA201001264B (en) 2011-07-27
WO2009033652A1 (en) 2009-03-19
US9498450B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
HRP20120046T1 (hr) Nerameksan za uporabu kod liječenja subakutnog tinitusa
EA201071054A1 (ru) Твердый препарат, растворяющийся во рту
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
RU2014145557A (ru) Комбинированный состав, содержащий многокомпонентную сфероидальную таблетку (мкст), заключенную в твердую капсулу, и способ его приготовления
ATE446744T1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
JP2009541443A5 (ko)
RU2010116863A (ru) Бупропиона гидробромид и его терапевтические применения
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
AR082493A1 (es) Formulaciones a base de nalbufina, y sus utilizaciones
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR112014009438A2 (pt) composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
AR051589A1 (es) Agentes terapeuticos
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
CR10801A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
RU2019109695A (ru) Лекарственная форма для пролонгированного ослабления симптомов
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
RS51211B (sr) Primena formulacija koje sadrže kapa-opioid receptor-agoniste za tretman disocijativnih poremećaja
MX2013005482A (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.